Precision Biosciences Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $45.1M-34.4% YoYTTM through 30 Jun 2026
Net Income -$52.7M-835.8% YoYTTM through 30 Jun 2026
Free Cash Flow -$51.9MTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| EBITDA Margin | -78.0% |
| Operating Margin | -152.0% |
| Net Margin | -117.0% |
Returns
-49.5%ROE
-29.6%ROA
Balance Sheet Health
Debt / Equity0.00x
Current Ratio13.32x
Net Debt-$137.2Mnet cash position
Cash & Equivalents$86.1M
Quality Metrics
Altman Z-Score-4.76
Piotroski F-Score1 / 9
FCF Margin-115.3%
Earnings-Beat Rate100.0%
Multi-Year Trend
RevenueFY2025: $34.3M
Diluted EPS-$1.25TTMFY2025: $-3.56
Dividend
No dividend
Capital Allocation
Capex Intensity0.1%
Segment Performance
No segment data available.
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.